CAS: 872728-85-3; Ethyl 3-(2-(((4-Carbamimidoylphenyl)Amino)Methyl)-1-Methyl-N-(Pyridin-2-yl)-1H-Benzo[d]Imidazole-5-Carboxamido)Propanoate 4-Methylbenzenesulfonate

该化合物是一种化学化合物,是Dagigatran的一种药物,是一种抗凝胶药物,用于预防和治疗血栓性失调,其特点是能够抑制在凝固级联中至关重要的素,这是一种酶素,可以减少血凝块的形成.该化合物通常以白色为白色,为非白色固体,在有机溶剂中溶解,便于吸收和转化成体内的活性形态.其分子结构包括一个乙基酯组和抗合糖合体,有助于其药性功能.Dagiggatran 乙酯抗血清是口服的,并因其可预测的药性特征而著称,这使得固定的剂量无需对凝固参数进行常规监测.通过临床试验确定安全性和功效,使其在抗凝固疗法中成为有价值的选择.正如任何药物,潜在副作用和抗逆作用一样,在使用这种化合物时必须遵循医学指导.

英文名称Ethyl 3-(2-(((4-Carbamimidoylphenyl)Amino)Methyl)-1-Methyl-N-(Pyridin-2-yl)-1H-Benzo[d]Imidazole-5-Carboxamido)Propanoate 4-Methylbenzenesulfonate
中文名称N-[[2-[[[4-(氨基亚氨基甲基)苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶基-β-丙氨酸乙酯 4-甲基苯磺酸盐
IUPAC名称ethyl 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate 4-methylbenzenesulfonate
其它别名N-[[2-[[[4-(Aminoiminomethyl)Phenyl]Amino]Methyl]-1-Methyl-1H-Benzimidazol-5-Yl]Arbonyl]-N-2-Pyridinyl-Beta-Alanine Ethyl Ester 4-Methylbenzenesulfonate; Intermediates Of Dabigatran; Ethyl 3-(((2R,3S,4R)-1-(2-(((4-Carbamimidoylphenyl)Amino)Methyl)-1-Methyl-1H-Benzo[d]Imidazol-; N-[[2-[[[4-(Aminoiminomethyl)Phenyl]Amino]Methyl]-1-Methyl-1H-Benzimidazol-5-Yl]Arbonyl]-N-2-Pyridin; N-[[2-[[[4-(Aminoiminomethyl)Phenyl]Amino]Methyl]-1-Methyl-1H-Benzimidazol-5-Yl]Arbonyl]-N-2-Pyridinyl-Beta-Alanine Ethyl Ester 4-Methylbenzenesulfona; Dabigatran Impurity 59; N-[[2-[[[4-(Aminoiminomethyl)Phenyl]Amino]Methyl]-1- Methyl-1H-Benzimidazol-5-Yl] Carbonyl]-N-2-Pyridinyl-Beta-Alanine Ethyl Ester 4-Methylbenzenesulfonate; N-[[2-[[[4-(Aminoiminomethyl)Phenyl]Amino]Methyl]-1- Methyl-1H-Benzimidazol-5-Yl]Carbonyl]-N-2-Pyridinyl-Beta-Alanine Ethyl Ester Tosylate
CAS编号872728-85-3
MFCD编号:MFCD22572335
分子式:C34H37N7O6S
分子量:671.78
产品CID: 1878996
产品分类生物化工 → 氨基酸及其衍生物 → 丙氨酸类衍生物

相似结构搜索
InChIKey: WENRCCRZLDFCGF-UHFFFAOYSA-N
InChI=1S/C27H29N7O3.C7H8O3S/c1-3-37-25(35)13-15-34(23-6-4-5-14-30-23)27(36)19-9-12-22-21(16-19)32-24(33(22)2)17-31-20-10-7-18(8-11-20)26(28)…
计算化学: 氢键受体数10.0氢键供体数4.0可旋转键数12.0

MSDS等安全信息

上下游产品

1-methyl-2-[N-[4-(1,2,4-oxadiazol-5-one-3-yl)phenyl]-amino-methyl]-benzimidazol-5-yl-carboxylic acid N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide toluene-4-sulfonic acid methanol 3-[[[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionic acid ethyl esterdabigatran etexilate ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate dabigatran etexilate N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl] amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-β-alanine ethyl ester methanesulfonate

合成工艺路线路线简述

Ethyl 3-(2-(Chloromethyl)-1-Methyl-N-(Pyridin-2-yl)-1H-Benzimidazole-6-Carboxamido)Propanate置于potassium Carbonate,对甲苯磺酸体系中,用乙醇,乙酸乙酯作为反应溶剂,化学反应生成 N-[[2-[[[4-(氨基亚氨基甲基)苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-2-吡啶基-Beta-丙氨酸乙酯 4-甲基苯磺酸盐
参考文献:一种非肽类凝血酶抑制剂达比加群酯的制备方法
标题:一种非肽类凝血酶抑制剂达比加群酯的制备方法
摘要:本发明公开了一种非肽类凝血酶抑制剂达比加群酯的制备方法,属于药物化学技术领域.本发明的技术方案要点为:一种非肽类凝血酶抑制剂达比加群酯的制备方法,其合成路线为:本发明反应条件温和,收率较高,成本低廉且适合产业化生产.

海关参考信息

2905121000-正丙醇
2909110000-乙醚
2912110000-甲醛
2912120000-乙醛
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-8471033-B2
优先权日:2008-06-16
标题 :Method for producing an intermediate product of dabigatran etexilate
发明人：FILSER CHRISTIAN; DERSCH WOLFGANG; HAMM RAINER; HAUSHERR ARNDT; KOCH GUNTER; SCHOLZ ULRICH; ZERBAN GEORG
权利人:FILSER CHRISTIAN; DERSCH WOLFGANG; HAMM RAINER; HAUSHERR ARNDT; KOCH GUNTER; SCHOLZ ULRICH; ZERBAN GEORG; BOEHRINGER INGELHEIM INT
摘要:The invention relates to a process for preparing the compound of formula 1 n na valuable intermediate product in the synthesis of the pharmaceutical active substance dabigatran etexilate.